AIMS: We aimed to study epidermal growth factor receptor (EGFR) expression in surgically resected pancreatic ductal adenocarcinomas (PDACs) by immunohistochemistry and their relationship to clinicopathological features, cell proliferation and cell adhesion protein expression. METHODS: A total of 99 PDACs were analysed on tissue microarrays for EGFR, E-cadherin and β-catenin expression patterns in tumour cells. The percentage of cells expressing the three proteins (membrane, cytoplasm or nuclear pattern) and of Ki67-positive tumour cells was assessed. Tumour protein expression was studied with regard to clinicomorphological features, Ki67 index and for postsurgical survival. RESULTS: Membrane tumour EGFR correlated with histological poor differentiation (dedifferentiation), increased number of mitoses and severe tumour cell atypia (pleiomorphism) as well as with aberrant adhesion protein expression such as nuclear β-catenin and cytoplasmic E-cadherin. Cytoplasmic tumour E-cadherin correlated with an increased Ki67-positive tumour cell component, whereas nuclear E-cadherin correlated with a shorter postsurgical overall survival, as well as with tumour necrosis and an abundant clear cell component. CONCLUSIONS: In conclusion, the results of our study suggest a complex role for EGFR in PDAC carcinogenesis, tumour expression of this protein being associated with tumour dedifferentiation, mitotic activity or pleiomorphism, as well as with aberrant tumour cell adhesion protein expression.
AIMS: We aimed to study epidermal growth factor receptor (EGFR) expression in surgically resected pancreatic ductal adenocarcinomas (PDACs) by immunohistochemistry and their relationship to clinicopathological features, cell proliferation and cell adhesion protein expression. METHODS: A total of 99 PDACs were analysed on tissue microarrays for EGFR, E-cadherin and β-catenin expression patterns in tumour cells. The percentage of cells expressing the three proteins (membrane, cytoplasm or nuclear pattern) and of Ki67-positive tumour cells was assessed. Tumour protein expression was studied with regard to clinicomorphological features, Ki67 index and for postsurgical survival. RESULTS: Membrane tumourEGFR correlated with histological poor differentiation (dedifferentiation), increased number of mitoses and severe tumour cell atypia (pleiomorphism) as well as with aberrant adhesion protein expression such as nuclear β-catenin and cytoplasmic E-cadherin. Cytoplasmic tumourE-cadherin correlated with an increased Ki67-positive tumour cell component, whereas nuclear E-cadherin correlated with a shorter postsurgical overall survival, as well as with tumour necrosis and an abundant clear cell component. CONCLUSIONS: In conclusion, the results of our study suggest a complex role for EGFR in PDAC carcinogenesis, tumour expression of this protein being associated with tumour dedifferentiation, mitotic activity or pleiomorphism, as well as with aberrant tumour cell adhesion protein expression.
Authors: Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther Journal: Biomark Res Date: 2021-06-05
Authors: Willemieke S Tummers; Arantza Farina-Sarasqueta; Martin C Boonstra; Hendrica A Prevoo; Cornelis F Sier; Jan S Mieog; Johannes Morreau; Casper H van Eijck; Peter J Kuppen; Cornelis J van de Velde; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg Journal: Oncotarget Date: 2017-05-26
Authors: F A Vuijk; L D A N de Muynck; L C Franken; O R Busch; J W Wilmink; M G Besselink; B A Bonsing; S S Bhairosingh; P J K Kuppen; J S D Mieog; C F M Sier; A L Vahrmeijer; J Verheij; A Fariňa-Sarasqueta; R J Swijnenburg Journal: Sci Rep Date: 2020-10-01 Impact factor: 4.379